Efficacy and safety of lumasiran for infants and young children with primary hyperoxaluria type 1: 30-month analysis of the phase 3 ILLUMINATE-B trial

Authors

Institutions

Publication Details

Journal
Frontiers in Pediatrics
Published
2024-09-16
DOI
https://doi.org/10.3389/fped.2024.1392644
Citations
7
Primary Topic
Kidney Stones and Urolithiasis Treatments
Type
article
Field-Weighted Citation Impact
2.93

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Efficacy and safety of lumasiran for infants and young children with primary hyperoxaluria type 1: 30-month analysis of the phase 3 ILLUMINATE-B trial

David J. Sas, Hadas Shasha‐Lavsky, John M. Gansner, Wesley Nathan Hayes et al.
7 citations
Frontiers in Pediatrics
Kidney Stones and Urolithiasis Treatments
2.93
article

Efficacy and safety of lumasiran for infants and young children with primary hyperoxaluria type 1: 30-month analysis of the phase 3 ILLUMINATE-B trial

David J. Sas, Hadas Shasha‐Lavsky, John M. Gansner, Wesley Nathan Hayes, Julien Hogan, Anne‐Laure Sellier‐Leclerc, Yaacov Frishberg, Mini Michael, Daniella Magen, Richard E. Willey
article en
7 citations

Abstract

No abstract available for this paper.
Frontiers in PediatricsVol. 12
Mayo Clinic (US), Bar-Ilan University (IL), Alnylam Pharmaceuticals (United States) (US), Inserm (FR), Technion – Israel Institute of Technology (IL), Hebrew University of Jerusalem (IL), Western Galilee Hospital (IL), Great Ormond Street Hospital (GB), Rambam Health Care Campus (IL), Shaare Zedek Medical Center (IL), Hôpital Femme Mère Enfant (FR), Assistance Publique – Hôpitaux de Paris (FR), Hospices Civils de Lyon (FR), Hôpital Robert-Debré (FR), Texas Children's Hospital (US), University College London (GB)
Alnylam Pharmaceuticals
Good health and well-being
Openalex Percentile: Top 8%
Kidney Stones and Urolithiasis Treatments
2.93
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Efficacy and safety of lumasiran for infants and young children with primary hyperoxaluria type 1: 30-month analysis of the phase 3 ILLUMINATE-B trial — David J. Sas, Hadas Shasha‐Lavsky, et al. · Frontiers in Pediatrics (2024) | TGRS Research Map | TGRS